Breaking News, Collaborations & Alliances

MacroGenics Earns $10M Janssen Milestone

Advances MGD011 into Phase I development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MacroGenics, Inc. has initiated dosing in a Phase I trial of MGD011 (also known as JNJ-64052781), triggering a $10 million milestone payment from partner Janssen Biotech. MGD011 incorporates MacroGenics’ platform for Dual-Affinity Re-Targeting (DART) to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies.     The Phase I trial will evaluate the safety, tolerability and preliminary clinical activity of MGD011 when administered to patients with relapsed or refra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters